No one would argue that knowing the number of stem cells present in any process involving them would not be important and valuable.
Boston, MA (PRWEB) January 14, 2016
In its first post after joining UK RegMedNet as an invited company sponsor, stem cell biomedicine technology company Asymmetrex, now headquartered in Boston, Massachusetts in the U.S, focused on distinguishing regenerative medicine (“RegMed”) companies from other biotechnology enterprises. Generally, RegMed companies do not fit well within common therapeutic and biotechnology classifications as “product” companies or as “platform technology” companies. Asymmetrex founder and director, James L. Sherley, M.D., Ph.D., suggests that instead the new classification, “stem cell fundamentals” companies, better describes the unifying motivation of RegMed companies. RegMed companies “seek to develop one or more fundamental biological properties of stem cells to address important unmet needs in medicine.”
The stem cell fundamental that motivates the business of Asymmetrex is asymmetric self-renewal. This is the biological process by which adult tissue stem cells divide to make simultaneously both unchanged new stem cells and sister cells committed to change to replenish or repair the organs and tissues of the body. Applying its unique expertise in asymmetric self-renewal research, Asymmetrex has developed patented technologies for addressing two important challenges in regenerative medicine, producing adult tissue stem cells and counting them. The goal of the company’s RegMedNet sponsorship is to better inform RegMedNet members of the vital advances that introducing adult tissue stem cell counting into their research and clinical practice would make.
No one would argue that knowing the number of stem cells present in any process involving them would not be important and valuable. Yet, currently, in basic research labs, clinical research labs, medical centers, and hospitals, worldwide, all relevant practices proceed without knowing tissue stem cell number, because this information has been unobtainable. Regenerative medicine battles forth with this same blind spot that stem cell biology has endured for more than half a century.
Asymmetrex has developed innovative technologies to end the non-quantitative state of regenerative medicine. These include new biomarkers with increased specificity for identifying adult tissue stem cells and a new computer simulation technology that is able to count many different types of human adult tissue stem cells. These technologies are an obvious set of new tools for accelerating advances in regenerative medicine. They also have valuable applications in other areas of biomedicine that are impacted by tissue stem cells, like drug development and environmental toxicology.
Asymmetrex plans to work with RegMedNet towards achieving a sea change in how its regenerative medicine community thinks about adult tissue stem cell number. The company’s technologies can demonstrate that in many settings it is now possible to count adult tissue stem cells, for the first time, to great advantage and value. Moving the fields of stem cell biology and regenerative medicine rapidly to a new standard of quantitative practice may take a bit of network chaos first. In the coming months, Asymmetrex will attempt to introduce just such a butterfly effect through RegMedNet to the broader regenerative medicine community.
Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine. Asymmetrex’s founder and director, James L. Sherley, M.D., Ph.D. is an internationally recognized expert on the unique properties of adult tissue stem cells. The company’s patent portfolio contains biotechnologies that solve the two main technical problems – production and quantification – that have stood in the way of successful commercialization of human adult tissue stem cells for regenerative medicine and drug development. In addition, the portfolio includes novel technologies for isolating cancer stem cells and producing induced pluripotent stem cells for disease research purposes. Currently, Asymmetrex’s focus is employing its technological advantages to develop facile methods for monitoring adult stem cell number and function in clinically important human tissues.